Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2003-04-09
2004-11-30
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S573000
Reexamination Certificate
active
06825232
ABSTRACT:
The present invention is directed to the use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammation. In particular, the invention relates to the use of such analogs in patients that are not suffering from dry eye for the treatment and prevention of ophthalmic inflammatory disorders involving cytokine secretion.
BACKGROUND OF THE INVENTION
15-Hydroxyeicosatetraenoic acid (“15-HETE”) is known to have inhibitory effects on leukotriene B4 production or its activity. See, for example, Zhu, et al., Skin Pharmacology and Applied Skin Physiology, 13(5):235-45 (September-October 2000); and Heitmann, et al., Experimental Dermatology, 4(2):74-8 (April 1995). 15-HETE is also reported to have minor anti-inflammatory properties in colitis. See Van Dijk, et al., Agents and Actions, 38 Spec. No. C120-1 (1993).
U.S. Pat. No. 5,696,166 (Yanni et al.) discloses compositions containing hydroxyeicosatetraenoic acid (“HETE”) derivatives and methods of using them topically for treating dry eye. Yanni et al. discovered that compositions comprising HETE derivatives increase ocular mucin secretion and are thus useful in treating dry eye.
Other than the use of 15-HETE and certain analogs for treating dry eye, HETE compounds have not been reported to be useful in treating inflammatory conditions of the eye, particularly in treating conditions involving the production of pro-inflammatory cytokines. Reports of the effects of 15-HETE and analogs of 15-HETE on cytokine inhibition in other tissues are varied. See, for example, Denizot, et al., Cytokine, 11(8):606-10 (August 1999) (“ . . . 15-HETE (1 &mgr;M to 0.1 nM) [has] no effect on the spontaneous and serum-induced production of IL-8 by human bone marrow stromal cells”); Denizot, et al., Cytokine, 10(10):781-5 (October 1998) (“ . . . 15-HETE . . . [has] no effect on the spontaneous, serum- and cytokine-induced IL-6 synthesis by bone marrow stromal cells; and WO 96/11908, which discloses that certain modified polyunsaturated fatty acids have the ability to suppress cytokine production and cytokine action and are useful as anti-malarial, anti-infective or anti-inflammatory agents. WO 96/11908 does not mention any ophthalmic inflammatory disorders.
SUMMARY OF THE INVENTION
The present invention is directed to methods of using HETE compounds to treat or prevent ophthalmic inflammatory conditions in patients that are not suffering from dry eye. In particular, the present invention is directed toward the topical ophthalmic use of HETE compounds to treat or prevent ophthalmic inflammatory conditions involving cytokines. Such ophthalmic inflammatory conditions include, but are not limited to, conjunctivitis; iritis; uveitis; episcleritis; scleritis; keratitis; endophthalmitis; and blepharitis.
REFERENCES:
patent: 4906467 (1990-03-01), Schwartzman et al.
patent: 5102670 (1992-04-01), Abraham et al.
patent: 5681854 (1997-10-01), Pang et al.
patent: 5696166 (1997-12-01), Yanni et al.
patent: 6174914 (2001-01-01), Yanni et al.
patent: 6255343 (2001-07-01), Belanger
patent: 6281192 (2001-08-01), Leahy et al.
patent: 6320062 (2001-11-01), Belanger
patent: 6326499 (2001-12-01), Belanger
patent: 6331566 (2001-12-01), Conrow et al.
patent: 6331644 (2001-12-01), Klimko et al.
patent: 6342525 (2002-01-01), Klimko et al.
patent: 6348496 (2002-02-01), Belanger
patent: 6353012 (2002-03-01), Hellberg et al.
patent: 6353022 (2002-03-01), Schneider et al.
patent: 6353032 (2002-03-01), Graff et al.
patent: 6376688 (2002-04-01), Ferrante et al.
patent: 6429227 (2002-08-01), Schneider et al.
patent: 6436994 (2002-08-01), Conrow et al.
patent: 6437160 (2002-08-01), Klimko et al.
patent: 6441035 (2002-08-01), Conrow et al.
patent: 6458853 (2002-10-01), Graff et al.
patent: 6458854 (2002-10-01), Graff et al.
patent: 6462061 (2002-10-01), Belanger
patent: 6552084 (2003-04-01), Klimko et al.
patent: 2002/0077358 (2002-06-01), Yanni et al.
patent: 1 251 736 (1989-03-01), None
patent: 0 097 059 (1983-12-01), None
patent: 0 132 089 (1985-01-01), None
patent: WO 92/04905 (1992-04-01), None
patent: WO 96/11908 (1996-04-01), None
patent: WO 99/43310 (1999-09-01), None
patent: WO 00/03705 (2000-01-01), None
patent: WO 00/53198 (2000-09-01), None
patent: WO 01/34549 (2001-05-01), None
Aldigier et al., “NZB/NZW F1 Mouse Nephritis and Immune Response are Not Changed by Treatment with a 15-Lipoxygenase Derivative,”Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 47, pp. 159-164 (1992).
Alpert et al., “15-HETE-substituted diglycerides selectively regulate PKC isotypes in human tracheal epithelial cells,”American J. of Physiology, vol. 277 (3), pp. 457-464 (1999).
Badr, “15-Lipoxygenase Products as Leukotriene Antagonists: Therapeutic Potential in Glomerulonephritis,”Kidney International, vol. 42 (Suppl. 38), pp. S-101-108 (1992).
Badr, “Lipoxygenases as Therapeutic Targets in the Acute and Subactue Phases of Glomerular Immune Injury,”Progression of Chronic Renal Diseases, Contrib Nephrol., vol. 118, pp. 113-125 (1998).
Buchanan et al., “Effects of 13-Hode and Other Momohydroxides on Integrin/Ligand Binding: Implications for Cell Interactions,”Adv. Exp. Med. Biology, vol. 433, pp. 265-269 (1997).
Camp et al., Inhibition of ionophore-stimulated leukotriene B4produciton in human leucocytes by monohydroxy fatty acids,British J. Phamacology, vol. 85, pp. 837-841 (1985).
Deleuran et al., “Cytokines in Rheumatoid Arthritis,”Scand. J. Rheumatol., vol. 25 (Suppl 104), pp. 1-38 (1996).
Denizot et al., “Effect of Cytokines and Lipid Mediators on the Synthesis of Interleukin 1&bgr; By Human Bone Marrow Stromal Cells,”Cytokine, vol. 12(5), pp. 499-502 (2000).
Denizot et al., “Effects of Lipid Mediators on the Synthesis of Leukaemia Inhibitor Factor and Interleukin 6 by Human Bone Marrow Stromal Cells,”Cytokine, vol. 10 (10), pp. 781-785 (1998).
Denizot et al., “Lipid Mediators Modulate the Synthesis of Interleukin 8 by Human-Bone Marrow Stromal Cells,”Cytokine, vol. 11(8), pp. 606-610 (1999).
Ferrante et al., “Altered Responses of Human Macrophages to Lipopolysaccharide by Hydroperoxy Eicosatetraenoic Acid, Hydroxy Eicosatetraenoic Acid, and Arachidonic Acid,”J. Clinical Invest., vol. 99(6), pp. 1445-1452 (1997).
Fogh et al., 15-Hydoxy-Eicosatetraenoic Acid (15-HETE) Inhibits Carrageenan-Induced Experimental Arthritis and Reduces Synovial Fluid Leukotrike B4(LTB4),Prostaglandins, vol. 37(2), pp. 213-228 (1989).
Fogh et al., Improvement of psoriasis vulgaris after intralesional injections of 15-hydroxyeicosatetraenoic acid (15-HETE),J. of the American Academy of Dermatology, vol. 18(2), pp. 279-285 (1988).
Graeber et al., “15-Hydroxyeicosatetraenoic Acid Stimulates Migration Human Retinal Microvessel Endothelium In Vitro and Neovascularization In Vivo,”Prostaglandins, vol. 39(6), pp. 665-673 (1990).
Hadjiagapiou et al., Metabolism of 15-Hydroxy-5,8,11,13-eicosatetraenoic Acid by MOLT-4 Cells and Blood T-lymphocytes,J. Biol. Chem., vol. 265(8), pp. 4369-4373 (1990).
Hamberg et al., “Identification of 15-hydroxy-5.8.11.13-eicosatetraenoic acid (15-HETE) as a major metabolite of arachidonic acid in human lung,” Acta Physiol Scand., vol. 110; pp. 219-221 (1980).
Haviv et al., “Structural Requirements for the Inhibition of 5-Lipoxygenase by 15-Hydroxyeicosa-5,8,11,13-tetraenooc Acid Analogues,” J. Med. Chem., vol. 30, pp. 254-263 (1987).
Heitmann et al., “Incorporation of 15-hydroxyeicosatrienoic acid in specific phospholipids of cultured human keratinocytes and psoriatic plaques,”Exp. Dermatol, vol. 4, pp. 74-78 (1995).
Hutchinson, “Arachidonate 15-lipoxygenase; characteristics and potential biological significance,” Eicosanoids, vol. 4, pp. 65-74 (1991).
Johnson et al., 15-Hydroxyeicosatetraenoic Acid is a Potent Inflammatory Mediator and Agonist of Canine Tracheal Mucus Secretion, from the Hypersensitivity Diseases Research, Lipids Research. The Upjohn Company, Kalamazoo, Michigan, pp. 917-922 (1984).
Kragbalie et al., “Intralesional Injection of 15(S)-Hydroxyeicosatetraenoic Acid in Psoriasis,”The Lancet, p. 509 (Aug. 30, 1986).
Lai et al., “Effect of inhaled 1
Alcon Inc.
Ryan Patrick M.
Weddington Kevin E.
LandOfFree
Use of hydroxyeicosatetraenoic acid compounds to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hydroxyeicosatetraenoic acid compounds to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hydroxyeicosatetraenoic acid compounds to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3340048